Novel nutraceutical supplement formulations
We prepared two formulations (Patent number: BR 10 2020 016156 3): Formulation 1 (n = 30): Novel Nutraceutical Supplement_(S) (without silymarin), developed and tested in the present study, contained the following components: zinc (Zn) 1%, magnesium (Mg) 1% (Purifarma Distribuidora Quımica e Farmacêutica, São Paulo, Brazil), FOSs 45% (NutraFlora®, Westchester, Illinois, USA), selenomethionine (Se) 0.01%, GOSs 10%, tixosil 5%, and 1.3/1.6-(b-glycosidic bonds) yeast b-glucans (Saccharomyces cerevisiae) 6% (Biorigin, São Paulo, Brazil); and Formulation 2 (n = 29): zinc (Zn) 1%, magnesium (Mg) 1% (Purifarma Distribuidora Química e Farmacêutica, São Paulo, Brazil), FOSs 45% (NutraFlora®, Westchester, Illinois, USA), selenomethionine (Se) 0.01%, GOSs 10%, tixosil 5%, 1.3/1.6-(b-glycosidic bonds) yeast b-glucans (Saccharomyces cerevisiae) 6% (Biorigin, São Paulo, Brazil), and S. marianum (silymarin extract 9%) (SM Empreendimento Farmacê utica LTDA, São Paulo, Brazil). The percentages of the Novel Nutraceutical Supplement were determined following recommendations and parameters published by the European Food Safety Authority (EFSA) (